Lung cancer * 9: Molecular biology of lung cancer: clinical implications
Open Access
- 1 October 2003
- Vol. 58 (10) , 892-900
- https://doi.org/10.1136/thorax.58.10.892
Abstract
It has been hypothesised that clinically evident lung cancers have accumulated many different genetic or epigenetic abnormalities in oncogenes and/or tumour suppressor genes. This notion has important clinical ramifications. Recent developments in our knowledge of the molecular biology of lung cancer are reviewed, with particular reference to genetic abnormalities in tumour suppressor gene inactivation and overactivity of growth promoting oncogenes. These changes lead to the “hallmarks of lung cancer”. These hallmarks are the new rational targets for early detection, prevention, and treatment of lung cancer.Keywords
This publication has 105 references indexed in Scilit:
- Expression of human telomerase subunit genes in primary lung cancer and its clinical significanceThe Annals of Thoracic Surgery, 2000
- Co-expression of epidermal growth factor receptor and transforming growth factor-α is independent of ras mutations in lung adenocarcinomaLung Cancer, 2000
- Differential Expression of the LAMB3 and LAMC2 Genes between Small Cell and Non-Small Cell Lung CarcinomasBiochemical and Biophysical Research Communications, 2000
- Promoter Methylation and Silencing of the Retinoic Acid Receptor- Gene in Lung CarcinomasJNCI Journal of the National Cancer Institute, 2000
- Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571Oncogene, 2000
- Evaluation of telomerase activity in bronchial lavage as a potential diagnostic marker for malignant lung diseaseLung Cancer, 2000
- The Hallmarks of CancerCell, 2000
- Early Lung Cancer Action Project: overall design and findings from baseline screeningThe Lancet, 1999
- Global cancer statisticsCA: A Cancer Journal for Clinicians, 1999
- Genetic Influence on Smoking — A Study of Male TwinsNew England Journal of Medicine, 1992